US Patent

US9370483 — Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Formulation · Assigned to Glenmark Specialty SA · Expires 2034-09-04 · 8y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a stable fixed dose pharmaceutical composition for nasal administration that contains mometasone or its salt and olopatadine or its salt.

USPTO Abstract

The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
US9370483
Jurisdiction
US
Classification
Formulation
Expires
2034-09-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Glenmark Specialty SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.